New York, New York--(Newsfile Corp. - March 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. ("Disc Medicine, Inc.") (NASDAQ: IRON) concerning...
NEW YORK , Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised...
Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with topline data expected in Q4 2026 ...
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
NEW YORK , Feb. 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised...
FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and that there is a strong mechanistic and biological plausibility supporting the use of the...
NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised...
NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised...
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Bitopertin was awarded the Commissioner’s National Priority Review Voucher (CNPV) and NDA is currently under FDA review Updated data from the Phase 2 study of DISC-0974 in patients with myelofibrosis...